帕金森病,有氧运动和光生物调节:一个随机对照试验
Luis Santos1, Johannes Burtscher2,3, Luis de Taboada4
1Department of Education Sciences, University of Oviedo, Campus de Llamaquique C/Aniceto Sela s/n, 33005, Oviedo, Spain. luis.santos@uniovi.es.
Journal of neural transmission (Vienna, Austria : 1996)
|October 31, 2025
概括
定期炼和光生物调节 (PBM) 对帕金森病 (PD) 症状显示出明显的益处. 然而,在本研究中,将运动与PBM结合起来没有产生协同效应.
科学领域:
- 神经学 神经学
- 生物医学工程 生物医学工程
- 康复医学 康复医学 康复医学
背景情况:
- 帕金森病 (PD) 是一种快速进展的神经系统疾病,目前没有疾病修饰治疗方法.
- 定期运动和光生物调节 (PBM) 正在成为PD的潜在治疗策略.
- 通过结合运动和PBM获得协同效益的潜力需要研究.
研究的目的:
- 调查有氧运动,PBM及其组合对帕金森病的运动和非运动症状的影响.
- 为了确定与单个干预相比,联合运动和PBM是否提供添加性或协同效应的好处.
- 评估对运动症状 (MDS-UPDRS),步态 (TMWT, TUG) 和姿势稳定性的影响.
主要方法:
- 一项随机临床试验,涉及72名患有PD的个体,被分配到运动,PBM (808 nm),运动+PBM或对照组六个月.
- 主要结局包括MDS-UPDRS,10米步行测试 (TMWT),定时上升和移动测试 (TUG) 和姿势学.
- 用ANOVA和非参数统计数据分析了53名受试者的数据.
主要成果:
- 运动显著改善了MDS-UPDRS分数和TMWT表现.
- 单独使用PBM就显示了后尿检结果的改善.
- 没有观察到对手握强度或上肢功能的显著影响;对于联合干预措施,没有发现添加或协同效应.
结论:
- 运动和PBM都单独解决了帕金森病的明显缺陷.
- 在这项研究中,将运动和PBM结合起来并没有产生更好的结果.
- 需要进一步的研究,以了解作用机制,并优化单独和与运动一起对PBM的个别治疗参数.
相关概念视频
Parkinson's Disease: Treatment
963
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
963
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K


